During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

The approval of Ziihera extends across European Union (EU) member states along with Norway, Iceland and Liechtenstein. The EC ...

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the “unfair” way they are assessed for use on the health service, a charity has warned. Breast Cancer Now ...

Jessie comically celebrated the fact that she’s been able to successfully go to the bathroom, writing, "I have now done a ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The Human Epidermal Growth Factor Receptor 2 (HER2) is one of the aggressive subtypes of breast cancer. The HER2 status decides the requirement of breast cancer patients to receive HER2-targeted ...

Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...